Search - tctmd.com

Displaying 1 - 20 of 486

Sort: Relevancy | Date

Loberamisal Scores a Rare Win for Stroke Neuroprotection

News Conference News ISC 2026

Loberamisal Scores a Rare Win for Stroke Neuroprotection

February 12, 2026

OPTION: IV Tenecteplase Boosts Outcomes Late After Non-LVO Stroke

News Conference News ISC 2026

OPTION: IV Tenecteplase Boosts Outcomes Late After Non-LVO Stroke

February 11, 2026

OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding

News Conference News ISC 2026

OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding

February 09, 2026

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

News Daily News

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

February 06, 2026

CHOICE-2 Bolsters Intra-arterial Lytics After Stroke Thrombectomy

News Conference News ISC 2026

CHOICE-2 Bolsters Intra-arterial Lytics After Stroke Thrombectomy

February 06, 2026

FASTEST Hints at Benefits of Hemostatic Therapy for Acute ICH in Select Groups

News Conference News ISC 2026

FASTEST Hints at Benefits of Hemostatic Therapy for Acute ICH in Select Groups

February 05, 2026

HF Care Differs Among Asian Subgroups in the US

News Daily News

HF Care Differs Among Asian Subgroups in the US

January 16, 2026

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

News Daily News

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Michael O'Riordan

January 09, 2026

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

News Daily News

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Yael L. Maxwell

November 10, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

November 08, 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

News Daily News

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Yael L. Maxwell

October 24, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.